Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06318871 · ClinicalTrials.gov registry record · Early Phase 1
Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma
A Early Phase 1 study of Renal Cell Carcinoma and Urothelial Carcinoma, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 2
- Study locations
NCT06318871 is a Early Phase 1 study of Renal Cell Carcinoma and Urothelial Carcinoma that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 10 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06318871, a Early Phase 1 study of Renal Cell Carcinoma and Urothelial Carcinoma, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this research study is to establish the safety and then to explore the effectiveness of infusing the combination of cytokine-induced memory-like (CIML) natural killer (NK) cells, a type of immune cell in the blood that is collected and bathed in special proteins to help identify and treat curtained advanced cancers, combined with low dose IL-2, which is a cytokine that activates immune cells, in advanced clear cell renal cell carcinoma and urothelial carcinoma. Names of the study therapies involved in this study are/is: * CIML NK cell therapy (a NK cell therapy) * IL-2 (a type of cytokine)
Conditions Studied
Interventions
- BIOLOGICAL Cytokine Induced Memory-like Natural Killer (CIML NK) Cells
- DRUG Interleukin-2 (IL-2)
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-08-28 |
| Est. Completion | 2031-07-28 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06318871
The ClinicalTrials.gov registry entry for NCT06318871 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (96% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Cytokine Induced Memory-like Natural Killer (CIML NK) Cells is the first listed.
NCT06318871 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06318871 about?
NCT06318871 is a clinical study titled "Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma". The goal of this research study is to establish the safety and then to explore the effectiveness of infusing the combination of cytokine-induced memory-like (CIML) natural killer (NK) cells, a type of immune cell in the blood that is collected and bathed in special proteins to help identify and trea...
What is the current status of trial NCT06318871?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2024-08-28. Estimated completion is 2031-07-28.
What conditions does trial NCT06318871 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma, Urothelial Carcinoma, Chromophobe Renal Cell Carcinoma, Renal Carcinoma, Translocation Renal Cell Carcinoma.
What interventions are being tested in trial NCT06318871?
The interventions under investigation include: Cytokine Induced Memory-like Natural Killer (CIML NK) Cells (BIOLOGICAL), Interleukin-2 (IL-2) (DRUG).
Who is sponsoring clinical trial NCT06318871?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06318871 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma
RECRUITING · Early Phase 1
-
Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma
RECRUITING · Early Phase 1
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
PET/MR for Characterization of Renal Masses (RMs)
RECRUITING
-
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
RECRUITING
-
Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.